Topadur Pharma AG
Disruptive drugs for aging diseases and conditions
TOPADUR is a a clinical-stage biopharmaceutical start-up company developing disruptive therapies for aging diseases. The company developed the DualTOP™ technology platform consisting of new dual-acting drugs that increase the levels of cGMP to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. TOPADUR’s R&D portfolio consists of promising candidates in regenerative medicine, oncology, ophthalmology and medical aesthetics. The DualTOP™ technology will contribute to promoting long healthy life. Topadur Pharma is preparing for an IPO in Switzerland for 2024/25
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
08.11.2024
Management transitions with industry veterans (startupticker.ch)
05.11.2024
Bio Europe in Stockholm hosts 33 Swiss companies (startupticker.ch)
06.06.2024
Oshen supports Topadur in the development of a treatment for alopecia (startupticker.ch)
06.05.2024
Innosuisse funded 45 Start-up innovation projects (startupticker.ch)
22.12.2023
Clinical progress for three Biotechs (startupticker.ch)
Last Tweets
01.09.2024
Start clinical phase 2a
01.04.2024
Partnering development TOP-M119
01.06.2023
Topadur receives EMA orphan drug designation
31.12.2022
Topadur successful completed safety study with topical TOP-N53 formulation and starts planning the clinical phase 2 program
31.12.2021
Topadur completed clinical phase 1 with lead product TOP-N53
No Jobs
Videos
Dual-mode-of- action
Startup Champions: venture leaders USA 2016 kick-off event (April 21st, 2016, EPFL)
Documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Leaders China
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
.png)
Swiss Economic Award 2019: Jungunternehmer des Jahres gesucht!
Der Swiss Economic Award ist der bedeutendste Jungunternehmerpreis der Schweiz. Herausragende unternehmerische Leistungen werden in den Kategorien «Dienstleistungen», «Hightech/Biotech» und «Produktion/Gewerbe» mit einem Preisgeld von je 25'000 Franken prämiert. On top gibt es: fundiertes Expertenfeedback, wertvolle Medienpräsenz und Zugang zum einzigartigen SEF-Netzwerk. Das zahlt sich doppelt aus für Jungunternehmer! Die Preisverleihung findet am Swiss Economic Forum am 24. Mai 2019 in Interlaken statt. News zu den Finalisten gibt’s laufend unter facebook.com/swisseconomic | twitter.com/swisseconomic | #SEFAward19 Hier bis zum 31. Januar 2019 bewerben
TOP 100 Scale-ups
Being among the TOP 100 Startups in Switzerland has become a seal of approval for founders, and the TOP 100 Swiss Startup Ranking provides them with the recognition they deserve. As startups cannot appear in the startup ranking for more than five years after incorporation, the TOP 100 Swiss Scale-up Ranking has been introduced. A growth jury is asked to select the TOP 100 Swiss Scale-ups. These companies, aged five up to 10 years, show the greatest potential for further growth and represent the future Swiss unicorns
Venture Leaders Life Sciences
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
Topadur Pharma AG
Disruptive drugs for aging diseases and conditions
Website:
www.topadur.com
Headquarter:
Schlieren
Foundation Date:
March 2015
Technology:
- Biotech
Sectors:
- Biotech
- Cosmetics
- Drug discovery
- Research and development
- Small molecule drugs
- Wound management
Support received
